Article

The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-Analysis

2024-07-03

Abstract excerpt

<h4>Background</h4> Colorectal cancer (CRC) ranks third globally in cancer-related mortality, with rising incidence, particularly in Asia, projecting a 60% surge by 2030. Metastatic CRC (mCRC) presents a significant challenge with a grim 5-year survival rate of 14%. Emerging evidence suggests that tumors with DNA mismatch repair deficiency (dMMR) and high microsatellite instability (MSI-H) respond well to immune c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f163447d-7f99-56e5-8982-7decc4eb2d9b
DOI: 10.1101/2024.07.02.24309865

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-AnalysisDOI 10.1101/2024.07.02.24309865Read

Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read

Unraveling Resistance to Immunotherapy in MSI-High Colorectal CancerSemantic proximity Read

Dual-immunotherapy triumphs: redefining deficient mismatch repair or high microsatellite instability metastatic colorectal cancer first-line treatmentSemantic proximity Read

Immunotherapy for the treatment of colorectal cancerSemantic proximity Read

Neoadjuvant Combination Immunotherapy for Colorectal Cancer: Clinical and Molecular Predictors of Pathological Complete Response and Safety AssessmentSemantic proximity Read

Safety and Efficacy of Triple Therapy Containing Encorafenib, Cetuximab, and Binimetinib for BRAF V600E-Mutated Colorectal Cancer: a Systematic Review and Meta-Analysis.Semantic proximity Read

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.Semantic proximity Read

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancerSemantic proximity Read

Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.Semantic proximity Read

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read

Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 StudySemantic proximity Read

Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.Semantic proximity Read